GSK vs. HALO: GSK vs. Halozyme Therapeutics Stock Comparison

Company Profile

GSK (GSK) and Halozyme Therapeutics (HALO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GSK is classified in Pharmaceuticals while HALO is classified in Biotechnology.

Halozyme Therapeutics (HALO) trades as ordinary local shares, while GSK (GSK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both companies show strong equity returns, but Halozyme Therapeutics (HALO) at 216.38% is the standout with ROE above its industry range; GSK (GSK) at 28.27% also sits in the top quartile.

Halozyme Therapeutics (HALO) at 26.93% keeps the most of each sales dollar — above its industry’s net margin range — and GSK (GSK) at 12.97% also retains a top-quartile share.

Both GSK (GSK) at 32.14% and Halozyme Therapeutics (HALO) at 59.84% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both GSK (GSK) at 4.11% and Halozyme Therapeutics (HALO) at 37.55% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

GSK (GSK) at 123.15% sits in the top EPS growth quartile, while Halozyme Therapeutics (HALO) at -25.36% is closer to the peer norm — faster per-share earnings growth for GSK.

Growth Metrics

Financial Strength

Halozyme Therapeutics (HALO) at 3.88 keeps current ratio within its industry’s typical mid-range, while GSK (GSK) at 0.86 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for GSK.

Only one side’s leverage can be read here: GSK (GSK) carries debt-to-equity ratio of 1.30 against its industry range, while Halozyme Therapeutics (HALO) reports no figure this period.

Financial Strength Metrics

Dividends

Halozyme Therapeutics (HALO) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile GSK (GSK) reports a yield of 1.57%, ranking against industry peers normally.

Halozyme Therapeutics (HALO) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile GSK (GSK) reports a payout of 63.33%, ranking against industry peers normally.

Dividend Metrics

Valuation

Both GSK (GSK) at 17.54 and Halozyme Therapeutics (HALO) at 25.91 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

GSK (GSK) at 3.01 sits in the cheaper P/S ratio quartile while Halozyme Therapeutics (HALO) at 6.55 prices around its industry’s middle — GSK costs less per dollar of sales, though read it alongside growth and margins.

Halozyme Therapeutics (HALO) reports a negative P/B ratio of -213.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile GSK (GSK) reports 4.02, ranking against industry peers normally.

Valuation Metrics